Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03262584 · ClinicalTrials.gov registry record
Evaluation of NGS for Detection and Follow-up of Fungal Pathogens in Immunocompromised Pediatric Patients
A clinical trial of Invasive Fungal Infections and Immunocompromised, sponsored by Karius.
- Completed
- Registry status
- 40
- Enrollment target
- 1
- Study location
NCT03262584 is a study of Invasive Fungal Infections and Immunocompromised that has completed, run by Karius. The registered enrollment target is 40 participants, roughly in line with the 42-participant average among 4 other Invasive Fungal Infections trials with a reported enrollment target. The trial reports 1 study location across 1 state.
The verdict
NCT03262584, a study of Invasive Fungal Infections and Immunocompromised, has completed, sponsored by Karius.
- COMPLETED
- Registry status
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
The Sponsor hypothesize that Next-generation Sequencing (NGS) can identify fungal pathogens, is more accurate than other noninvasive options and can report fungal genomic load.
Conditions Studied
Study Locations (1)
Illinois
- Ann & Robert H. Lurie Children's Hospital of Chicago - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2017-05-17 |
| Est. Completion | 2018-09-28 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03262584
The ClinicalTrials.gov registry entry for NCT03262584 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 42-participant average among 4 other Invasive Fungal Infections trials with a reported enrollment target. The listed sponsor is Karius, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Invasive Fungal Infections appearing as the primary indexed condition, and to 0 interventions.
NCT03262584 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.
Frequently Asked Questions
What is clinical trial NCT03262584 about?
NCT03262584 is a clinical study titled "Evaluation of NGS for Detection and Follow-up of Fungal Pathogens in Immunocompromised Pediatric Patients". The Sponsor hypothesize that Next-generation Sequencing (NGS) can identify fungal pathogens, is more accurate than other noninvasive options and can report fungal genomic load.
What is the current status of trial NCT03262584?
This trial is currently completed. The enrollment target is 40 participants. The study started on 2017-05-17. Estimated completion is 2018-09-28.
What conditions does trial NCT03262584 study?
This clinical trial studies the following conditions: Invasive Fungal Infections, Immunocompromised, Invasive Fungal Disease, Fever and Neutropenia.
Who is sponsoring clinical trial NCT03262584?
This trial is sponsored by Karius, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03262584 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Invasive Fungal Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Biodistribution and Pathophysiology Study of 18F-Fluorodeoxysorbitol (18F-FDS) in Diseased Patients
COMPLETED
-
Oral Posaconazole Three Times Per Day vs Weekly High Dose Amphotericin B Lipid Complex (ABLC)
COMPLETED · Phase 3
-
Endemic Mycoses Treatment With SUBA-itraconazole vs Itraconazole
COMPLETED · Phase 2
-
A Bioequivalence Study of APX001 High-load and Low-load Tablets
COMPLETED · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.